Draxis Specialty Pharmaceuticals Inc. Sustainability Profile
Draxis Specialty Pharmaceuticals Inc., often referred to simply as Draxis, is a prominent player in the pharmaceutical industry, headquartered in California. Founded in the early 2000s, the company has established itself as a leader in the development and commercialisation of specialty pharmaceuticals, particularly in the areas of oncology and pain management. Draxis is renowned for its innovative drug delivery systems and unique formulations that enhance patient outcomes. With a strong focus on research and development, the company has achieved significant milestones, including the successful launch of several proprietary products that address unmet medical needs. Positioned strategically within the market, Draxis Specialty Pharmaceuticals has garnered recognition for its commitment to quality and efficacy, making it a trusted name among healthcare professionals and patients alike.
DitchCarbon Score
How does Draxis Specialty Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Draxis Specialty Pharmaceuticals Inc.'s score of 52 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Draxis Specialty Pharmaceuticals Inc., headquartered in California, currently does not report specific carbon emissions data for the most recent year. The company is a current subsidiary of Jubilant Pharmova Limited, which provides emissions data cascaded from its operations. However, no specific emissions figures or reduction targets have been disclosed for Draxis. As part of its corporate family, Draxis may align with broader sustainability initiatives and commitments from Jubilant Pharmova Limited, although specific details regarding these initiatives are not provided. The absence of reported emissions data suggests that Draxis may still be in the process of establishing its own climate commitments or may rely on the sustainability framework of its parent company. In summary, while Draxis Specialty Pharmaceuticals Inc. does not currently present specific emissions data or reduction targets, it is positioned within a corporate structure that may influence its future climate strategies and commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 894,456,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 107,906,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 12,057,000 | - | - | - | 00,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Draxis Specialty Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is Draxis Specialty Pharmaceuticals Inc.'s Location?
Draxis Specialty Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Draxis Specialty Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
